Comerica Bank Reduces Holdings in Integra LifeSciences Holdings Corporation $IART

Key Points

• Comerica Bank has reduced its stake in Integra LifeSciences by 21.8%, now owning 62,176 shares valued at approximately $1.37 million after selling 17,284 shares during the first quarter.
• Despite the decline in Comerica Bank's holdings, other institutional investors have increased their positions, with the Arizona State Retirement System and others lifting their stakes in the same period.
• Integra LifeSciences’ stock recently opened at $15.13, with analysts projecting a current fiscal year EPS of 2.45 amidst mixed ratings from financial analysts.

Comerica Bank trimmed its position in Integra LifeSciences Holdings Corporation (NASDAQ:IART - Free Report) by 21.8% during the first quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 62,176 shares of the life sciences company's stock after selling 17,284 shares during the quarter. Comerica Bank owned 0.08% of Integra LifeSciences worth $1,367,000 at the end of the most recent quarter.

Several other hedge funds have also recently added to or reduced their stakes in IART. Systematic Financial Management LP lifted its holdings in shares of Integra LifeSciences by 8.9% during the 1st quarter. Systematic Financial Management LP now owns 936,834 shares of the life sciences company's stock valued at $20,601,000 after buying an additional 76,271 shares during the last quarter. Hsbc Holdings PLC increased its holdings in shares of Integra LifeSciences by 303.6% in the first quarter. Hsbc Holdings PLC now owns 40,323 shares of the life sciences company's stock worth $887,000 after acquiring an additional 30,331 shares in the last quarter. Quantbot Technologies LP raised its position in Integra LifeSciences by 151.6% in the 1st quarter. Quantbot Technologies LP now owns 19,825 shares of the life sciences company's stock valued at $436,000 after buying an additional 11,944 shares during the last quarter. Wellington Management Group LLP grew its stake in Integra LifeSciences by 10.4% in the first quarter. Wellington Management Group LLP now owns 2,766,125 shares of the life sciences company's stock valued at $60,827,000 after purchasing an additional 259,987 shares in the last quarter. Finally, Tejara Capital Ltd acquired a new stake in Integra LifeSciences during the 1st quarter worth approximately $1,209,000. Institutional investors own 84.78% of the company's stock.

Integra LifeSciences Trading Down 2.9%

Shares of NASDAQ IART traded down $0.46 during trading on Monday, reaching $15.53. The company had a trading volume of 520,838 shares, compared to its average volume of 1,048,372. The stock has a market cap of $1.21 billion, a P/E ratio of -2.38, a PEG ratio of 0.90 and a beta of 1.20. Integra LifeSciences Holdings Corporation has a 12 month low of $11.06 and a 12 month high of $27.13. The company's fifty day moving average price is $13.39 and its 200-day moving average price is $15.69. The company has a quick ratio of 0.73, a current ratio of 1.23 and a debt-to-equity ratio of 1.18.

Integra LifeSciences (NASDAQ:IART - Get Free Report) last posted its quarterly earnings data on Thursday, July 31st. The life sciences company reported $0.45 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.43 by $0.02. Integra LifeSciences had a positive return on equity of 12.15% and a negative net margin of 30.87%.The company had revenue of $415.61 million during the quarter, compared to analyst estimates of $395.06 million. During the same quarter last year, the company earned $0.63 earnings per share. The firm's quarterly revenue was down .6% on a year-over-year basis. Integra LifeSciences has set its FY 2025 guidance at 2.190-2.290 EPS. Q3 2025 guidance at 0.400-0.450 EPS. As a group, research analysts expect that Integra LifeSciences Holdings Corporation will post 2.45 earnings per share for the current year.

About Integra LifeSciences

Integra LifeSciences Holdings Corporation manufactures and sells surgical instruments, neurosurgical products, and wound care products for use in neurosurgery, neurocritical care, and otolaryngology. It operates in two segments, Codman Specialty Surgical and Tissue Technologies. The company offers neurosurgery and neuro critical care products, including tissue ablation equipment, dural repair products, cerebral spinal fluid management devices, intracranial monitoring equipment, and cranial stabilization equipment; and surgical headlamps and instrumentation, as well as after-market services.